Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 13/20 | 0.65 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GLA | P06280 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2035165 | 0.99 | TPSAB1 (0.64) | TPSAB1CNR1KDM4EALDH1A1GLA | |
| SCHEMBL12643147 | 0.89 | TPSAB1 (0.65) | TPSAB1CNR1KDM4EALDH1A1GLA | |
| SCHEMBL12642988 | 0.89 | TPSAB1 (0.72) | TPSAB1CNR1KDM4EALDH1A1GLA | |
| Hydrochloric Acid SCHEMBL12542366 | 0.89 | TPSAB1 (0.65) | TPSAB1CNR1KDM4EALDH1A1GLA | |
| Hydrochloric Acid SCHEMBL12544272 | 0.88 | TPSAB1 (0.71) | TPSAB1CNR1KDM4EALDH1A1GLA | |
| SCHEMBL2037677 | 0.87 | TPSAB1 (0.59) | TPSAB1CNR1KDM4EALDH1A1GLA | |
| SCHEMBL12642994 | 0.82 | TPSAB1 (0.76) | TPSAB1 | |
| SCHEMBL12643112 | 0.82 | TPSAB1 (0.69) | TPSAB1CNR1KDM4EALDH1A1GLA | |
| SCHEMBL12643107 | 0.82 | TPSAB1 (0.62) | TPSAB1CNR1KDM4EALDH1A1GLA | |
| SCHEMBL12642928 | 0.82 | TPSAB1 (0.69) | TPSAB1CNR1KDM4EALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | TPSAB1 1/4885CNR1 160/4885KDM4E 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.